Scholarlink

<p>In this study, we aimed to elucidate the role of the gut microbiome in the multistage progression of colorectal cancer (CRC). We analyse the gut bacterial composition of three clinical groups: healthy individuals, patients with precancerous polyps (adenomas), and patients with cancerous tumours (carcinomas). Biopsy samples were profiled using the Illumina MiSeq platform. Significant differences in the composition of the gut microbiota emerged between the groups. The tumour-associated microbiome showed increased bacterial diversity and specific enrichments, including Verrucomicrobia (genus Akkermansia) and specific Bacteroidetes (genera Porphyromonas and Prevotella). In contrast, the healthy group exhibited a higher abundance of specific protobacteria (genus Microvirga). In particular, the adenoma group also showed elevated levels of specific bacteria compared to the control group. Our findings suggest a possible link between the gut microbiome and the progression of CRC, with variations observed at different stages of the disease. This opens avenues for further investigation of the potential of the gut microbiome as a biomarker and therapeutic target for prevention and management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization of Gut Microbiota Composition in Colorectal Adenoma and Carcinoma Patients Compared to Healthy Controls

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月15日

查看全文
  • Lenka Wachsmannová,
  • Silvia Dulanská,
  • Miloslav Karhánek,
  • Viola Števurková,
  • Soňa Čierniková,
  • Vanda Repiská,
  • Jakub Styk,
  • Katarína Šoltys,
  • Michal Trnka

摘要

In this study, we aimed to elucidate the role of the gut microbiome in the multistage progression of colorectal cancer (CRC). We analyse the gut bacterial composition of three clinical groups: healthy individuals, patients with precancerous polyps (adenomas), and patients with cancerous tumours (carcinomas). Biopsy samples were profiled using the Illumina MiSeq platform. Significant differences in the composition of the gut microbiota emerged between the groups. The tumour-associated microbiome showed increased bacterial diversity and specific enrichments, including Verrucomicrobia (genus Akkermansia) and specific Bacteroidetes (genera Porphyromonas and Prevotella). In contrast, the healthy group exhibited a higher abundance of specific protobacteria (genus Microvirga). In particular, the adenoma group also showed elevated levels of specific bacteria compared to the control group. Our findings suggest a possible link between the gut microbiome and the progression of CRC, with variations observed at different stages of the disease. This opens avenues for further investigation of the potential of the gut microbiome as a biomarker and therapeutic target for prevention and management.